Gazatte
Independent journalism
  • Gold$3,578.59▼ down 1.28%
  • Bitcoin$61,705.33▼ down 0.75%
  • EUR/USD1.0981▲ up 0.12%
  • USD/ILS3.3293▲ up 0.92%
  • Ethereum$1,742.04▼ down 1.05%
  • GBP/USD1.3109▲ up 0.14%
  • USD/EGP53.81▼ down 0.02%
  • Silver$42.44▼ down 0.97%
  • USD/JPY158.90▼ down 0.45%
  • USD/TRY50.58▲ up 0.01%
  • USD/JOD0.70900.00%
  • USD/SAR3.7553▲ up 0.05%
  • Gold$3,578.59▼ down 1.28%
  • Bitcoin$61,705.33▼ down 0.75%
  • EUR/USD1.0981▲ up 0.12%
  • USD/ILS3.3293▲ up 0.92%
  • Ethereum$1,742.04▼ down 1.05%
  • GBP/USD1.3109▲ up 0.14%
  • USD/EGP53.81▼ down 0.02%
  • Silver$42.44▼ down 0.97%
  • USD/JPY158.90▼ down 0.45%
  • USD/TRY50.58▲ up 0.01%
  • USD/JOD0.70900.00%
  • USD/SAR3.7553▲ up 0.05%
Skip to content
Gazatte
Middle EastPalestineWorldPoliticsBusinessCultureOpinionMarkets
Gazatte
Menu
Log in

Sections

Middle EastLebanonSyriaYemenGulfIran-Israel War
PalestineGazaWest BankJerusalemPalestinians of '48
WorldAmericasRussia-Ukraine WarEuropeAsia-PacificAfricaMore world news
PoliticsU.S. PoliticsEuropean PoliticsElectionsDiplomacy & Foreign PolicyInternational Law & Human Rights
BusinessCurrent
Culture
Opinion
Sports
Travel
Language
GazatteMiddle East & World News
Log in
/
Gazatte
BusinessCultureOpinionMarkets
  1. Business & Economy

Novo Nordisk sues Eli Lilly over alleged false advertising claims

Novo Nordisk has filed a lawsuit against Eli Lilly, accusing the U.S. drugmaker of misleading advertising over claims that its weight-loss treatments outperform Novo’s competing medications.

By Gazatte Staff

21 July 2026, 12:04 GMT · Updated 6 October 2026, 11:08 GMT · 1 min read ·

Novo Nordisk sues Eli Lilly over alleged false advertising claims

Novo Nordisk announced on Tuesday that it is suing rival Eli Lilly in a U.S. federal court, accusing the American pharmaceutical company of false advertising for claiming that its weight-loss drugs are superior to Novo’s treatments.

The Danish company said it filed the lawsuit in the U.S. District Court in New Jersey, alleging that Lilly violated federal and state false advertising and unfair competition laws, including the Lanham Act, through nationwide advertising campaigns for its obesity drug Zepbound and diabetes treatment Mounjaro.

Novo alleges that Lilly compared the highest approved doses of its own medications with lower doses of Novo’s Wegovy and Ozempic, while leaving out newer higher-dose versions that Novo says deliver greater weight-loss results.

Novo said it is seeking a court order requiring Lilly to withdraw the advertisements and launch a corrective advertising campaign. The company added that it plans to request a temporary injunction if Lilly does not voluntarily remove the advertisements.

Novo said it sent a warning letter to Lilly in April following U.S. approval of a 7.2 milligram dose of Wegovy. Novo’s legal counsel, John Kockelman, said Lilly did not respond to the letter and instead only included what he described as an insufficient disclaimer in its advertisements.

Kockelman said Lilly’s advertisements compare weight-loss results of about 50 pounds for Zepbound with around 33 pounds for Wegovy, despite the lack of a direct comparative study between the highest approved doses of the two drugs. He added that separate late-stage trials of the highest doses showed average weight losses of about 48 pounds for Zepbound and 47 pounds for Wegovy.

More in Business & Economy
  • AI INDUSTRYNvidia crisis puts AI investment and chip exports under scrutiny
  • FUEL PRICE CRISISMorocco expands transport aid as fuel prices approach record highs
  • WINTER GAS SUPPLIESEuropean gas prices fall as forecasts point to milder weather
  • SUPERMARKET REFRIGERATION FAILURESEuropean supermarkets pull food after refrigeration cyber incidents
Gazatte follows its Editorial Policy. Spotted an error? Tell us.

Add Gazatte as a preferred source on Google

More in Business & Economy

  • AI INDUSTRYNvidia crisis puts AI investment and chip exports under scrutiny
  • FUEL PRICE CRISISMorocco expands transport aid as fuel prices approach record highs
  • WINTER GAS SUPPLIESEuropean gas prices fall as forecasts point to milder weather
  • SUPERMARKET REFRIGERATION FAILURESEuropean supermarkets pull food after refrigeration cyber incidents

More from Business & Economy

  • Gold slips towards $4,000 as dollar firms before Fed decision
    GOLD AND INTEREST RATES

    Gold slips towards $4,000 as dollar firms before Fed decision

  • Gold, dollar and Swiss franc diverge as markets seek safety
    GLOBAL SAFE-HAVEN ASSETS

    Gold, dollar and Swiss franc diverge as markets seek safety

  • Google Cloud outage disrupts Revolut and UK banking services
    CLOUD SERVICE DISRUPTION

    Google Cloud outage disrupts Revolut and UK banking services

  • Suncor agrees $860 million sale of Canadian stakes to Ithaca
    OFFSHORE OIL DEAL

    Suncor agrees $860 million sale of Canadian stakes to Ithaca

  • Niger advances Russian energy ties as uranium dispute persists
    NUCLEAR ENERGY COOPERATION

    Niger advances Russian energy ties as uranium dispute persists

  • Iran’s inflation squeeze reaches affluent households as war erodes purchasing power
    IRAN ECONOMY

    Iran’s inflation squeeze reaches affluent households as war erodes purchasing power

Gazatte

Independent news and analysis on the Middle East and the world.

Follow us
Add Gazatte as a preferred source on Google

Sections

  • Latest news
  • Markets
  • Palestine
  • Middle East
  • Politics & Diplomacy
  • Opinion
  • Business & Economy

About Gazatte

  • About Us
  • Our Newsroom
  • Editorial Policy
  • Corrections
  • Ownership & Funding

Contact

  • WhatsApp +44 7488 813779
  • support@gazatte.co
  • Contact Us

© Gazatte. All rights reserved.

  • Privacy Policy
  • Terms of Use
  • Cookie Policy